None listed
Conditions
Brief summary
This is an observational study looking at the rate of human leukocyte antigen (HLA) antibodies developing in patients who receive a specific blood product, HLA compatible red cells. The aim is to confirm that this product can be transfused without HLA antibodies to the blood donor developing. Blood will be taken before and 4-8 weeks after the transfusion.
Interventions
Transfusions with HLA compatible red cells.
Information collected: brief medical history and demographic information (age, sex) from the product request form at enrolment.
Participants are not actively involved in the study; data will be directly collected from Lifeblood records including request form and pre- and post-transfusion HLA antibody request forms and sera.
Observation will continue until the time of the post-transfusion antibody test (approximately 4-8 weeks post-transfusion), noting
Transfusions with HLA compatible red cells. Information collected: brief medical history and demographic information (age, sex) from the product request form at enrolment. Participants are not actively involved in the study; data will be directly collected from Lifeblood records including request form and pre- and post-transfusion HLA antibody request forms and sera. Observation will continue until the time of the post-transfusion antibody test (approximately 4-8 weeks post-transfusion), noting that patients can b re-recruited to the study if a further request is received.
Sponsors
Australian Red Cross Lifeblood
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Patients supplied with HLA compatible red cells by Australian Red Cross Lifeblood.
Exclusion criteria
Patients will be excluded if no HLA testing has been performed by the conclusion of the study.
Outcome results
None listed